Oppenheimer Asset Management Inc. Reduces Holdings in Kenvue Inc. $KVUE

Oppenheimer Asset Management Inc. decreased its position in shares of Kenvue Inc. (NYSE:KVUE) by 8.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,226,543 shares of the company’s stock after selling 114,511 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Kenvue were worth $25,672,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in KVUE. Pittenger & Anderson Inc. purchased a new stake in Kenvue during the 1st quarter worth $30,000. Trust Co. of Vermont increased its position in shares of Kenvue by 266.8% in the 2nd quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock worth $33,000 after purchasing an additional 1,150 shares during the last quarter. TruNorth Capital Management LLC bought a new stake in shares of Kenvue in the 1st quarter worth about $36,000. Truvestments Capital LLC bought a new stake in shares of Kenvue in the 1st quarter worth about $37,000. Finally, Clal Insurance Enterprises Holdings Ltd boosted its stake in Kenvue by 378.5% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock valued at $39,000 after purchasing an additional 1,287 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Trading Down 0.6%

Shares of NYSE:KVUE opened at $15.00 on Friday. The company has a 50 day moving average of $17.91 and a 200-day moving average of $20.79. The firm has a market cap of $28.78 billion, a P/E ratio of 20.26, a P/E/G ratio of 2.16 and a beta of 0.72. Kenvue Inc. has a twelve month low of $14.05 and a twelve month high of $25.17. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The company had revenue of $3.84 billion during the quarter, compared to analyst estimates of $3.94 billion. During the same period in the prior year, the business posted $0.32 EPS. The business’s revenue for the quarter was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were paid a dividend of $0.2075 per share. This is a boost from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.83 annualized dividend and a yield of 5.5%. The ex-dividend date of this dividend was Wednesday, August 13th. Kenvue’s dividend payout ratio (DPR) is currently 112.16%.

Analysts Set New Price Targets

KVUE has been the subject of a number of analyst reports. UBS Group reduced their target price on shares of Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a research note on Wednesday, October 8th. Barclays reduced their target price on shares of Kenvue from $20.00 to $17.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 1st. Citigroup reduced their target price on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, October 9th. Weiss Ratings reissued a “hold (c-)” rating on shares of Kenvue in a research note on Tuesday, October 14th. Finally, Zacks Research raised shares of Kenvue to a “strong sell” rating in a research note on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $20.75.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.